TABLE 3 | Additional year 1 efficacy endpoints in the VISION trials*
From the following article:
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Eugene W. M. Ng, David T. Shima, Perry Calias, Emmett T. Cunningham, Jr., David R. Guyer & Anthony P. Adamis
Nature Reviews Drug Discovery 5, 123-132 (February 2006)
doi:10.1038/nrd1955
| Endpoints | Pegaptanib 0.3 mg (n = 294) | Sham (n = 296) |
|---|---|---|
Maintain/gaining  0 lines | 98 (33) | 67 (23) |
| p value versus sham | 0.003 | |
| Gaining 1 line | 64 (22) | 36 (12) |
| p value versus sham | 0.004 | |
| Gaining 2 lines | 33 (11) | 17 (6) |
| p value versus sham | 0.02 | |
| Gaining 3 lines | 18 (6) | 6 (2) |
| p value versus sham | 0.04 | |
| Losing 6 lines | 28 (10) | 65 (22) |
| p value versus sham | <0.001 | |
| Visual acuity 20/200 or worse (legal blindness in study eye) | 111 (38) | 165 (56) |
| p value versus sham | <0.001 | |
| *Intention-to-treat population, n = 1,186; for missing data, the last observation carried forward method was used. Data are numbers of patients (%) unless otherwise noted; p values from the Cochran–Mantel–Haenszel test. VISION, VEGF Inhibition Study in Ocular Neovascularization. Note: this table does not present an exhaustive list of all categories, nor are all categories mutually exclusive. Adapted from Ref. 78. | ||
Download file
If the slide opens in your browser, select "File > Save As" to save it.